Clinical and Pathologic Features Influencing Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 18, Issue 2, 2014, Pages 340-347

  Weber, Cynthia E ^a   Bock, Eileen A ^a   Hurtuk, Michael G ^a   Abood, Gerard J ^a   Pickleman, Jack ^a   Shoup, Margo ^c   Aranha, Gerard V ^a,b,d  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

^c Department of Surgery Division of Surgical Oncology   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lymph node ratio; Pancreatic ductal adenocarcinoma; Pancreaticoduodenectomy

Indexed keywords

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ANASTOMOSIS LEAKAGE; FEMALE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; LENGTH OF STAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; OPERATION DURATION; OPERATIVE BLOOD LOSS; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; REOPERATION; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; TIME; TUMOR INVASION; VERY ELDERLY;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANASTOMOTIC LEAK; BLOOD LOSS, SURGICAL; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OPERATIVE TIME; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84895907853     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2388-x     Document Type: Review

References (28)

1. Cancer Society Facts & Figures 2012. www. cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941. pdf Accessed 24 April 2013.
2. American Cancer Society: Pancreatic Cancer. www. cancer. org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics Accessed 24 April 2013.
3. Wentz SC, Zhao ZG, Shyr Y, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 2012; 4(10): 207-215.
4. You DD, Lee HG, Heo JS, Choi SH, Choi DW. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2009; 13(9): 1699-1706.
5. Bhatti I, Peacock O, Awan AK, Semeraro D, Larvin M, Hall RI. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg 2010; 34(4): 768-775.
6. Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006; 33(3): 240-245.
7. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Amer Surg 2004; 70(3): 235-240.
8. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10(10): 1338-1346.
9. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ. 1423 pancreaticoduodenectomies for pancreatic cancer: a single institution experience. J Gastrointest Surg 2006; 10(9): 1199-1210.
10. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012; 152(3 Suppl 1): S43-49.
11. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141(5): 610-618.
12. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008; 15(1): 165-174.
13. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008; 143(12): 1166-1171.
14. Ueda M, Endo I, Nakashima M, Minami Y, Kazuhisa T, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H. Prognostic factors after resection of pancreatic cancer. World J Surg 2009; 33(1): 104-110.
15. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13(7): 1337-1344.
16. House MG, Gonen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y, Brennan MF, Allen PJ. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007; 11(11): 1549-1555.
17. Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Muller JM. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 200; 17(1): 29-35.
18. La Torre, M, Cavallini M, Ramacciato G, Cosenza G, Del Monte SR, Nigri G, Ferri M, Mercantini P, Ziparo V. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. J Surg Oncol 2011; 104(6): 629-633.
19. Casadei R, Ricci C, Pezzilli R, Calculli L, D'Ambra M, Taffurelli G, Minni F. Assessment of complications according to the Clavien-Dindo Classification after distal pancreatectomy. Journal of Pancreas (Online) 2011; 12(2): 126-130.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
21. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, Clavien PA. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006; 244: 931-939.
22. Aranha GV, Aaron JM, Shoup M. Critical analysis of a large series of pancreaticogastrostomy after pancreaticoduodenectomy. Arch Surg 2006; 141(6): 574-579.
23. Aranha GV, Hodul PJ, Creech S, Jacobs W. Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy. J Am Coll Surg 2003; 197(2): 223-231.
24. Gooiker GA, van Gijn W, Wouters MW, Post PN, van de Velde CJ, Tollenaar RA, and on behalf of the Signalling Committee Cancer of the Dutch Cancer Society. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic cancer. Br J Surg 2011; 98(4): 485-494.
25. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245(5): 777-783.
26. Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, Fernandez-del Castillo C, Warshaw AL, Thayer SP. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2013; 17(2): 257-266.
27. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517.
28. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ. A prospective, randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618-628.